GSK-3

PurMinds Appoints Leading Drug Designer, Dr. Alan Kozikowski, to Chief Scientific Officer and Appoints Pharma Veteran Dr. Max Arella to Scientific Advisory Board

Retrieved on: 
Thursday, November 9, 2023
ALS, AD, CSO, Therapy, GSK-3, Invention, Publication, Research, Drug development, NCE, Myenteric plexus, Risk, Alzheimer's disease, Neuroscience, HDAC6, HDAC, DSM-IV codes, Chemistry, SAB, United States Air Force Scientific Advisory Board, Pharmaceutical industry, Medical device

Dr. Kozikowski is a Global leader in medicinal chemistry designing Novel Chemical Entities (NCEs) for oncology and neuroscience.

Key Points: 
  • Dr. Kozikowski is a Global leader in medicinal chemistry designing Novel Chemical Entities (NCEs) for oncology and neuroscience.
  • Dr. Arella is a seasoned drug development and technology transfer expert and former drug scout for big pharmaceutical companies.
  • Dr. Arella served as Chief Scientist and member of Scientific Advisory Boards of small, medium and large pharmaceuticals companies since 1996.
  • Previously PurMinds' acting CSO, Dr. Arella was instrumental in guiding PurMinds' business strategy in drug development.

PurMinds Acquires Novel Chemical Entity HDAC6 Inhibitor for Neurological Disorders

Retrieved on: 
Thursday, September 28, 2023
NCE, Axonal transport, Neuron, Therapy, Disease, HDAC, GSK-3, DSM-IV codes, Nutrient, Research, CMT, Multiple sclerosis, HDAC6, Neuroscience, Acquisition, Parkinson's disease, Alzheimer's disease, Charcot–Marie–Tooth disease, Pharmaceutical industry, ALS

Toronto, Ontario--(Newsfile Corp. - September 28, 2023) - PurMinds NeuroPharma ("PurMinds" or the "Company"), a neuroscience company with a robust clinical pipeline combining small molecules, psychedelic compounds and other modalities, pursuing breakthrough therapeutic solutions for neurological disorders hallmarked by neurodegeneration, today announced completion of acquisition of a small molecule novel chemical entity (NCE) known as SW-200, a non-hydroxamic acid that shows superior histone deacetylase 6 (HDAC6) selectivity.

Key Points: 
  • Toronto, Ontario--(Newsfile Corp. - September 28, 2023) - PurMinds NeuroPharma ("PurMinds" or the "Company"), a neuroscience company with a robust clinical pipeline combining small molecules, psychedelic compounds and other modalities, pursuing breakthrough therapeutic solutions for neurological disorders hallmarked by neurodegeneration, today announced completion of acquisition of a small molecule novel chemical entity (NCE) known as SW-200, a non-hydroxamic acid that shows superior histone deacetylase 6 (HDAC6) selectivity.
  • Drugs that inhibit the molecular target HDAC6 are a novel class of therapeutics that are able to functionally enhance the axonal transport of nutrients, growth factors and neurotransmitters in neurons.
  • Encouraged by scientific studies that have shown efficacy in rodent models of neurodegenerative disorders, PurMinds NeuroPharma anticipates the successful development of an HDAC6 inhibitor for Charcot-Marie Tooth Disease (CMT) - a progressive neurodegenerative disorder, which causes disabling deficits in nerve function affecting 1 in 2500 people with no current cure.
  • "HDAC6 inhibition represents an innovative therapeutic target to address a range of neurological conditions currently without a cure.

PurMinds Appoints Leading Drug Designer, Dr. Alan Kozikowski to the Scientific Advisory Board

Retrieved on: 
Friday, September 8, 2023
Psychiatry, SAB, NCE, Drug development, Therapy, HDAC, GSK-3, DSM-IV codes, Cancer, United States Air Force Scientific Advisory Board, Research, Montreal Cognitive Assessment, Invention, Chemistry, CICI, Neuroscience, Parkinson's disease, Publication, Myenteric plexus, Pharmaceutical industry

Toronto, Ontario--(Newsfile Corp. - September 8, 2023) - PurMinds NeuroPharma ("PurMinds" or the "Company"), a Canadian neuroscience company with a robust clinical pipeline combining small molecules, psychedelic compounds and other modalities, pursuing breakthrough therapeutic solutions for neurological disorders marred by neurodegeneration, today announced the appointment of one of the world's leading drug designer, Professor Alan Kozikowski, Ph.D., to the Company's Scientific Advisory Board ("SAB").

Key Points: 
  • Toronto, Ontario--(Newsfile Corp. - September 8, 2023) - PurMinds NeuroPharma ("PurMinds" or the "Company"), a Canadian neuroscience company with a robust clinical pipeline combining small molecules, psychedelic compounds and other modalities, pursuing breakthrough therapeutic solutions for neurological disorders marred by neurodegeneration, today announced the appointment of one of the world's leading drug designer, Professor Alan Kozikowski, Ph.D., to the Company's Scientific Advisory Board ("SAB").
  • Dr. Kozikowski is a Global leader in medicinal chemistry designing Novel Chemical Entities (NCEs) for oncology and neuroscience.
  • A number of his inventions are in various stages of clinical development or are now marketed drugs.
  • "We continue to expand the scientific and technological expertise of our SAB and the addition of Dr. Kozikowski is an incredibly exciting development for PurMinds.

UPDATE -- Actuate Therapeutics Announces Poster Presentations at the 2023 AACR Annual Meeting

Retrieved on: 
Monday, April 10, 2023
Actuate, Abstract, GSK-3, AACR, American Association for Cancer Research, Therapy, Pharmaceutical industry

CHICAGO and FORT WORTH, Texas, April 10, 2023 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (Actuate), a clinical stage biopharmaceutical company, announced today three poster presentations from scientific collaborators at the upcoming American Association for Cancer Research (AACR) Annual Meeting, taking place April 14-19, 2023, in Orlando, Florida.

Key Points: 
  • CHICAGO and FORT WORTH, Texas, April 10, 2023 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (Actuate), a clinical stage biopharmaceutical company, announced today three poster presentations from scientific collaborators at the upcoming American Association for Cancer Research (AACR) Annual Meeting, taking place April 14-19, 2023, in Orlando, Florida.
  • The abstracts are currently available on the AACR meeting website .
  • The posters will be available online at https://actuatetherapeutics.com/news-media/ following the presentations.
  • Abstract CT222 / 12: Multimodal mechanism of action of the GSK-3 inhibitor 9-ING-41 (elraglusib) includes an immunomodulatory component: preliminary results from the 1801 phase 1/2 trial

Actuate Therapeutics Announces Poster Presentations at the 2023 AACR Annual Meeting

Retrieved on: 
Monday, April 10, 2023
Actuate, Abstract, GSK-3, AACR, American Association for Cancer Research, Therapy, Pharmaceutical industry

CHICAGO and FORT WORTH, Texas, April 10, 2023 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (Actuate), a clinical stage biopharmaceutical company, announced today three poster presentations from scientific collaborators at the upcoming American Association for Cancer Research (AACR) Annual Meeting, taking place April 14-19, 2023, in Orlando, Florida.

Key Points: 
  • CHICAGO and FORT WORTH, Texas, April 10, 2023 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (Actuate), a clinical stage biopharmaceutical company, announced today three poster presentations from scientific collaborators at the upcoming American Association for Cancer Research (AACR) Annual Meeting, taking place April 14-19, 2023, in Orlando, Florida.
  • The abstracts are currently available on the AACR meeting website .
  • The posters will be available online at https://actuatetherapeutics.com/news-media/ following the presentations.
  • Abstract CT222 / 12: Multimodal mechanism of action of the GSK-3 inhibitor 9-ING-41 (elraglusib) includes an immunomodulatory component: preliminary results from the 1801 phase 1/2 trial

Actuate Therapeutics Congratulates Dr. Patricia LoRusso on Being Named AACR President-Elect

Retrieved on: 
Thursday, March 23, 2023
AACR, Mayo Clinic, University, Education, Cancer research, American Society of Clinical Oncology, GSK-3, United States Air Force Scientific Advisory Board, MD Anderson Cancer Center, Doctor of Philosophy, CRUK, NAC, ASCO, Organization, DO, Food and Drug Administration Amendments Act of 2007, Patient, Clinical professor, American Association for Cancer Research, FDA, Therapy, Society, Food, Pharmaceutical industry, Actuate

CHICAGO and FORT WORTH, Texas, March 23, 2023 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc., a Chicago-based clinical-stage biopharmaceutical company advancing lead drug elraglusib (a novel GSK-3 inhibitor), today announced that Patricia M. LoRusso, DO, PhD (hc), a member of its Scientific Advisory Board, has been elected as President-Elect of the American Association of Cancer Research for 2023-2024.

Key Points: 
  • CHICAGO and FORT WORTH, Texas, March 23, 2023 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc., a Chicago-based clinical-stage biopharmaceutical company advancing lead drug elraglusib (a novel GSK-3 inhibitor), today announced that Patricia M. LoRusso, DO, PhD (hc), a member of its Scientific Advisory Board, has been elected as President-Elect of the American Association of Cancer Research for 2023-2024.
  • “We congratulate Dr. LoRusso for being elected to lead the AACR and for her significant contributions to the field of cancer research and therapeutic development,” said Daniel M. Schmitt, President & CEO of Actuate.
  • “As a founding member of Actuate’s Scientific Advisory Board, Dr. LoRusso has played an invaluable role in designing the innovative accelerated clinical development plans for elraglusib, Actuate’s best-in-class agent, for the benefit of adult and pediatric patients with difficult-to-treat cancers.”
    Dr. LoRusso joined the Actuate Scientific Advisory Board in October 2015.
  • She also has worked closely with Cancer Research United Kingdom (CRUK), as the chair of their New Agents Committee (NAC).

Actuate Therapeutics Congratulates Dr. Patricia LoRusso on Being Named AACR President-Elect

Retrieved on: 
Thursday, March 23, 2023
AACR, Mayo Clinic, University, Education, Cancer research, American Society of Clinical Oncology, GSK-3, United States Air Force Scientific Advisory Board, MD Anderson Cancer Center, Doctor of Philosophy, CRUK, NAC, ASCO, Organization, DO, Food and Drug Administration Amendments Act of 2007, Patient, Clinical professor, American Association for Cancer Research, FDA, Therapy, Society, Food, Pharmaceutical industry, Actuate

CHICAGO and FORT WORTH, Texas, March 23, 2023 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc., a Chicago-based clinical-stage biopharmaceutical company advancing lead drug elraglusib (a novel GSK-3 inhibitor), today announced that Patricia M. LoRusso, DO, PhD (hc), a member of its Scientific Advisory Board has been Elected as President-Elect the American Association of Cancer Research for 2023-2024.

Key Points: 
  • CHICAGO and FORT WORTH, Texas, March 23, 2023 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc., a Chicago-based clinical-stage biopharmaceutical company advancing lead drug elraglusib (a novel GSK-3 inhibitor), today announced that Patricia M. LoRusso, DO, PhD (hc), a member of its Scientific Advisory Board has been Elected as President-Elect the American Association of Cancer Research for 2023-2024.
  • “We congratulate Dr. Russo for being elected to lead the AACR and for her significant contributions to the field of cancer research and therapeutic development” said Daniel M. Schmitt, President & CEO of Actuate.
  • Dr. LoRusso has served in leadership positions of several other organizations, including the education and scientific committees of the American Society of Clinical Oncology (ASCO), and the steering committee for the Food and Drug Administration (FDA) Accelerating Anticancer Agent Development and Validation Workshop.
  • She also has worked closely with Cancer Research United Kingdom (CRUK), as the chair of their New Agents Committee (NAC).

DGAP-News: MorphoSys's Licensing Partner GSK Shared Preliminary Results From OSCAR Study with Otilimab for the Treatment of Severe Pulmonary COVID-19 Related Disease

Retrieved on: 
Tuesday, March 2, 2021
MorphoSys, Health, Industry economics), Monoclonal antibodies, GlaxoSmithKline, Otilimab, GSK-3, Coronavirus disease, TecDAX, Respiratory disease, the OSCAR study, MorphoSys

MorphoSys's Licensing Partner GSK Shared Preliminary Results From OSCAR Study with Otilimab for the Treatment of Severe Pulmonary COVID-19 Related Disease; Expanding the Study for Patients 70 Years and Older

Key Points: 
  • MorphoSys's Licensing Partner GSK Shared Preliminary Results From OSCAR Study with Otilimab for the Treatment of Severe Pulmonary COVID-19 Related Disease; Expanding the Study for Patients 70 Years and Older
    MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ: MOR), a commercial-stage biopharmaceutical company and a leader in antibody, protein and peptide technologies, announced today that its licensing partner GlaxoSmithKline plc (LSE/NYSE: GSK) reported preliminary results of the OSCAR (Otilimabin Severe COVID-19 Related Disease) study using otilimab (formerly MOR103/GSK3196165) for the treatment of severe pulmonary COVID-19 related disease.
  • Otilimab is an investigational human monoclonal antibody directed against GM-CSF (granulocyte-macrophage colony-stimulating factor) that was generated by MorphoSys and outlicensed to GSK in 2013.
  • GSK is also developing otilimab for the treatment of rheumatoid arthritis in the ongoing Phase 3 ContRAst trials.
  • "The preliminary study results with otilimab are encouraging news for patients 70 and older with severe COVID-19 related pulmonary disease," said Dr. Malte Peters, Chief Research and Development Officer of MorphoSys AG.

Glycogen Synthase Kinase 3 (GSK3) inhibitor Pipeline Insight 2021: Key Players Involved are AMO Pharma, Actuate Therapeutics, Rock Creek Pharmaceuticals, BCN Biosciences & HitGen - ResearchAndMarkets.com

Retrieved on: 
Friday, February 19, 2021
Health, General Health, Enzymes, Protein kinases, Biology of bipolar disorder, GSK-3, GSK, Glycogen synthase, Kinase, Signal transduction

The "Glycogen Synthase Kinase 3 (GSK3) inhibitor - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Glycogen Synthase Kinase 3 (GSK3) inhibitor - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This "Glycogen Synthase Kinase 3 (GSK3) inhibitor - Pipeline Insight, 2021," report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Glycogen Synthase Kinase 3 (GSK3) inhibitor pipeline landscape.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Glycogen Synthase Kinase 3 (GSK3) inhibitor R&D.
  • Glycogen Synthase Kinase 3 (GSK3) inhibitor pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.